MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 140 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 1.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,201,987 | -74.0% | 124,637 | -58.9% | 0.61% | -70.0% |
| Q2 2023 | $69,989,997 | -55.6% | 302,987 | -53.4% | 2.03% | -56.5% |
| Q1 2023 | $157,605,150 | -47.4% | 650,562 | -37.0% | 4.65% | -44.7% |
| Q4 2022 | $299,518,263 | +1292.3% | 1,031,932 | +211.7% | 8.41% | +1247.9% |
| Q3 2022 | $21,513,000 | -18.2% | 331,023 | -9.9% | 0.62% | -24.3% |
| Q2 2022 | $26,306,000 | -3.7% | 367,501 | +32.1% | 0.82% | +50.6% |
| Q1 2022 | $27,305,000 | +86.5% | 278,286 | +61.0% | 0.55% | +384.1% |
| Q4 2021 | $14,644,000 | +2989.5% | 172,800 | +7708.4% | 0.11% | +769.2% |
| Q3 2018 | $474,000 | -94.7% | 2,213 | -93.1% | 0.01% | -94.5% |
| Q2 2018 | $9,010,000 | -45.9% | 32,213 | -77.4% | 0.24% | -49.4% |
| Q1 2018 | $16,645,000 | -4.0% | 142,522 | -24.5% | 0.47% | -19.0% |
| Q4 2017 | $17,338,000 | – | 188,893 | – | 0.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tao Capital Management LP | 77,657 | $5,047,000 | 3.31% |
| L1 Capital Pty Ltd | 161,163 | $10,474,000 | 2.05% |
| Avoro Capital Advisors LLC | 1,535,000 | $99,760,000 | 1.84% |
| Affinity Asset Advisors, LLC | 100,000 | $6,499,000 | 1.81% |
| GREAT POINT PARTNERS LLC | 95,500 | $6,207,000 | 1.50% |
| ARMISTICE CAPITAL, LLC | 1,236,000 | $80,328,000 | 1.39% |
| Affinity Asset Advisors, LLC | 75,000 | $4,874,000 | 1.36% |
| MPM BioImpact LLC | 44,747 | $2,908,000 | 0.69% |
| Baker Brothers Advisors | 1,499,213 | $97,434,000 | 0.64% |
| Perceptive Advisors | 331,023 | $21,513,000 | 0.62% |